Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab in Glioblastoma
NCT02336165Phase 2Completed
- Sponsor
- Ludwig Cancer Research
- Start
- Feb 2015
- Primary completion
- Nov 2018
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 2
01
Overview
Phase 2, open-label trial of durvalumab in glioblastoma (GBM) (5 cohorts), sponsored by Ludwig Cancer Research. Primary endpoints: Overall Survival Rate at 12 Months, Progression-free Survival Rate at 6 Months and 1 more. Started Feb 2015; status: completed.
02
Drugs
durvalumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02336165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02336165.